Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cidara Therapeutics, Inc. - Common Stock
(NQ:
CDTX
)
221.28
+0.25 (+0.11%)
Streaming Delayed Price
Updated: 3:45 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cidara Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
November 14, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Via
Chartmill
Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal
↗
November 14, 2025
The company is getting deeper into the antiviral space, buying a company working on a long-acting drug to protect against flu.
Via
Investor's Business Daily
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
↗
November 14, 2025
Via
Benzinga
Nasdaq Dips Over 300 Points; Applied Materials Posts Upbeat Q4 Earnings
↗
November 14, 2025
Via
Benzinga
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral
↗
October 09, 2025
Via
Stocktwits
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Merck Makes Big Bet On Flu Protection With Cidara Buyout
↗
November 14, 2025
Merck (NYSE: MRK) to acquire Cidara (NASDAQ: CDTX) for $9.2 billion, diversifying its portfolio with CD388.
Via
Benzinga
Discover the top movers in Friday's pre-market session.
↗
November 14, 2025
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Via
Chartmill
CDTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Cidara Therapeutics, Inc. is Fair to Shareholders
November 14, 2025
From
Halper Sadeh LLC
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 14, 2025
Via
Benzinga
Merck To Buy Cidara In $9.2B Deal To Strengthen Antiviral Portfolio
↗
November 14, 2025
With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications.
Via
Stocktwits
Topics
Intellectual Property
Why RLX Technology Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
↗
November 14, 2025
Via
Benzinga
Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight?
↗
November 14, 2025
Cidara Therapeutics shares jumped over 42% in after-hours trading following a 13D filing and Phase 3 enrollment milestone.
Via
Benzinga
Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium
↗
November 13, 2025
Via
Stocktwits
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday
↗
October 27, 2025
Via
Benzinga
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is 'Strategically Attractive'
↗
October 10, 2025
JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388's game-changing potential.
Via
Benzinga
Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage
↗
October 10, 2025
Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading higher on Friday after the biotech company made a recent announcement about their presentation at the upcoming ESWI 2025 conference. JP Morgan...
Via
Benzinga
Why Cidara Therapeutics Stock Crushed It Today
↗
October 09, 2025
The company earned an important fast-track review designation for a pipeline medication.
Via
The Motley Fool
Cidara Shares Are Trading Higher Friday: What's Going On?
↗
October 03, 2025
Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing.
Via
Benzinga
Why Cidara Therapeutics Was Such a Healthy Stock Today
↗
September 26, 2025
The company could have quite a winner on its hands with its most advanced pipeline drug.
Via
The Motley Fool
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today
↗
September 24, 2025
Via
Stocktwits
Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Five-Year High
↗
September 24, 2025
The company is accelerating plans to run Phase 3 testing of its non-vaccine flu prevention drug by six months.
Via
Investor's Business Daily
Topics
Intellectual Property
Cidara (CDTX) Q2 Cash Surges 163%
↗
August 07, 2025
Via
The Motley Fool
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
↗
June 30, 2025
With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?
Via
MarketBeat
FedEx Issues Soft Guidance, Joins Torrid Holdings, Allot And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
June 25, 2025
Via
Benzinga
Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
↗
June 25, 2025
Via
Benzinga
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
June 24, 2025
Via
Benzinga
Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering
↗
June 23, 2025
The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor.
Via
Stocktwits
What's going on in today's session
↗
June 23, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.